Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

Abstract: The present invention relates to a variant of a parent polypeptide comprising an Fc fragment, wherein the variant exhibits an increased affinity for at least one of the Fc (FcR) fragment receptors selected from among Fc?RIIIa (CD16a), Fc?RIIa (CD32a), and Fc?RIIb (CD32b) receptors, relative to that of the parent polypeptide, characterized in that it comprises at least one mutation chosen from among K290G, Y296W, V240H, V240I, V240M, V240N, V240S, F241H, F241Y, L242A, L242F, L242G, L242H, L242I, L242K, L242P, L242S, L242T, L242V, F243L, F243S, E258G, E258I, E258R, E258M, E258Q, E258Y, V259C, V259I, V259L, T260A, T260H, T260I, T260M, T260N, T260R, T260S, T260W, V262A, V262S, V263T, V264L, V264S, V264T, V266L, V266M, S267A, S267Q, S267V, K290D, K290E, K290H, K290L, K290N, K290Q, K290R, K290S, K290Y, P291G, P291Q, P291R, R292I, R292L, E293A, E293D, E293G, E293M, E293Q, E293S, E293T, E294A, E294G, E294P, E294Q, E294R, E294T, E294V, Q295I, Q295M, Y296H, S298A, S298R, Y300I, Y300V, Y300W, R301A, R301M, R301P, R301S,

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

Abstract: Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.

Abstract: The present invention relates to a composition comprising, in a physiologically acceptable medium: a) at least one saccharide, b) at least one amino acid, c) DMSO or at least one C3-C5 alkanediol, d) at least one antioxidant, and e) cells for therapeutic purposes, said composition having a pH between 7.0 and 8.5, preferably between 7.0 and 8.3. It also relates to a method for the cryopreservation of at least one sample of cells for therapeutic purposes, comprising the following steps: i) mixing the sample of cells for therapeutic purposes with ingredients a) to d) above and a physiologically acceptable medium, so as to obtain a composition having a pH between 7.0 and 8.5, preferably between 7.0 and 8.3, then ii) freezing the composition obtained in step i).

Abstract: The disclosure relates to uses, methods and compositions for the inactivation of pathogens in biological compositions, using a glycol as a pathogen inactivating agent.

Abstract: Disclosed is a composition including, in a physiologically acceptable medium: a) human albumin; b) at least one saccharide; c) DMSO and L-cysteine or coenzyme Q10; and d) cells for therapeutic purposes, with the exception of specific tumour-infiltrating lymphocytes.

Abstract: The invention relates to a new method for obtaining aptamers directed against protein targets comprising a histidine-containing surface domain, and aptamers obtaining by said method.

Abstract: Disclosed is a method for filtering a fibrinogen composition, comprising the following steps: a) purifying the fibrinogen composition by chromatographic purification using an elution buffer comprising arginine; b) optionally, at least one step of filtering the fibrinogen composition obtained by chromatographic elution in step a), on a filter having a pore size of between 0.08 ?m and 0.22 ?m, c) filtering the fibrinogen composition obtained by chromatographic elution in step a), or optionally obtained in step b), on a symmetrical filter having a pore size of between 15 nm and 25 nm, and preferably between 18 nm and 22 nm, and d) recovering the resulting fibrinogen solution, the filtering method being carried out without adding arginine after step a), at a high capacity and without a prior freezing and/or thawing step.

Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.

Abstract: The present invention relates to a composition comprising, in a physiologically acceptable medium: a) at least one saccharide, b) at least one amino acid, c) DMSO or at least one C3-C5 alkanediol, d) at least one antioxidant, and e) cells for therapeutic purposes, said composition having a pH between 7.0 and 8.5, preferably between 7.0 and 8.3. It also relates to a method for the cryopreservation of at least one sample of cells for therapeutic purposes, comprising the following steps: i) mixing the sample of cells for therapeutic purposes with ingredients a) to d) above and a physiologically acceptable medium, so as to obtain a composition having a pH between 7.0 and 8.5, preferably between 7.0 and 8.3, then ii) freezing the composition obtained in step i).

Abstract: The invention proposes the use of a pharmaceutical composition comprising 200 g/L immunoglobulin G (IgG), between 200 and 250 mM glycine and between 15 and 25 ppm nonionic detergent particularly suitable for subcutaneous administration. In addition, the pH of the composition is between 4.6 and 5.0.

Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.

Abstract: The present invention relates to a pharmaceutical composition for oral delivery, including an anti tumour necrosis factor alpha (TNF.alpha.) antibody, preferably a monoclonal antibody produced in the milk of a transgenic non-human animal, and which can be combined advantageously with caprylic acid, and is preferably in a form that is suitable for targeted release of the antibody in the intestine.

Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.

Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.

Abstract: Highly effective combinations of a compound of formula A (a PI3K? selective inhibitor) and anti-CD20 antibodies are provided herein for the treatment and amelioration of PI3K? and/or CD20 mediated diseases and disorderes. In particular, the combination can be used to treat cancers and autoimmune diseases. More particularly, the invention provided for a combination of a compound of formula A, or stereoisomers thereof, and ublituximab for the treatment and/or amerioration of hematological malignancies such as leukemia and lymphoma.

Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.

Abstract: The invention relates to an affinity chromatography matrix, as a gel, comprising polymeric particles on which at least one oligosaccharide corresponding to a blood group A epitope and/or blood group B is grafted, via a spacer, characterized in that the density of oligosaccharides is comprised between 0.2 and 0.7 mg/ml of matrix. The invention also relates to the uses of this matrix for preparing concentrates of immunoglobulins for therapeutic use.